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(57) ABSTRACT 
Several aromatic hydrocarbons di-substituted with a 
polyamine are described according to formulas selected from 
compounds 4, 7, 10, 15 and pharmaceutically acceptable salts 
thereof. The novel dimeric polyamines of the present inven-
tion demonstrate enhanced penetration into cells having an 
upregulated polyamine transport system, such as various 
types of cancer cells. The disclosed aromatic polyamine 
dimers provide highly efficient drugs for targeting cancer 
cells with active polyamine transporters. 
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POLYAMINE TRANSPORTER SELECTIVE 
COMPOUNDS AS ANTI-CANCER AGENTS 
RELATED APPLICATION 
This application claims priority from provisional applica-
tion Ser. No. 60/915,448, which was filed on May 2, 2007, 
and which is incorporated herein by reference in its entirety. 
FIELD OF THE INVENTION 10 
2 
conjugate' s formula comprises compound 4 or pharmaceuti-
cally acceptable salts thereof. Also included is a naphthyl 
conjugate di-substituted with homospermidine, wherein said 
conjugate' s formula comprises compound 7 or pharmaceuti-
cally acceptable salts thereof. Part of the invention is a benzyl 
conjugate di-substituted with homospermidine, wherein said 
conjugate has a formula selected from compounds 10, 15, 
mixtures thereof and pharmaceutically acceptable salts 
thereof. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
The present invention relates to the field of cancer treat-
ment and, more particularly, to polyamines which, due to 
their special structure, preferentially enter cells having an 
upregulated polyamine transport system. 
BACKGROUND OF THE INVENTION 
15 apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. 1 is a chemical flow diagram showing a synthetic 
20 scheme for making compounds 3 and 4 according to an 
embodiment of the present invention; 
Polyamines are essential growth factors for cells. All cells 
have methods of manufacturing polyamines from aminoacid 
sources. In addition cells can import polyamines from outside 
the cell via a process referred to as the polyamine transporter 
(PAT). While much is known about polyamine transport in 
bacteria, yeast and Leishmania spp., the mammalian 
polyamine transporter is a measureable, yet poorly described 25 
import process. It is an important cancer target because many 
cancer cells are unable to produce enough polyamines to 
sustain their growth rate and rely on polyamine import in 
order to grow. Accordingly, certain polyamines are important 
vectors for delivery of agents into cells via the cells' 30 
polyamine transport system. 
SUMMARY OF THE INVENTION 
With the foregoing in mind, the present invention advan- 35 
tageously provides several aromatic hydrocarbons di-substi-
tuted with a polyamine. These compounds are useful treat-
ment agents and gain entrance into cells via the cell's own 
polyamine transport system. In this manner, one can append 
a polyamine architecture to a polycyclic aromatic architec- 40 
ture and facilitate its import into cells via the polyamine 
transporter. In this sense, the polyamine acts as a drug deliv-
ery 'vector', which assists cellular uptake of the attached 
aromatic system. The presently disclosed hydrocarbons have 
formulasaccordingtocompounds4, 7, 10, 15,asshowninthe 45 
figures, and include pharmaceutically acceptable salts thereof 
as well as conjugates. 
The invention also includes a pharmaceutically acceptable 
composition containing at least one aromatic hydrocarbon 
di-substituted with a polyamine, said hydrocarbon's formula 50 
being selected from compounds 4, 7, 10, 15 and pharmaceu-
tically acceptable salts thereof. 
The invention further includes a method of treating a cell, 
the method comprising contacting the cell with a compound 
or conjugate selected from compounds 4, 7, 10, 15, combi- 55 
nations thereof and their pharmaceutically acceptable salts. 
Preferably, in the method the cell being treated is a cancer cell 
or a cell with an increased level oftopoisomerase Ila. Where 
the cell being treated expresses an increased level of topoi-
somerase Ila and the compound, conjugate, combination or 60 
pharmaceutically acceptable salt selected preferably com-
prises compound 4. 
The invention additionally includes several conjugates 
employing compounds 4, 7, 10 and 15 as treatment agents 
which are delivered via a cell's own polyamine transport 65 
system. For example, the invention includes an anthracene 
conjugate di-substituted with homospermidine, wherein said 
FIG. 2 shows a diagram of a synthetic scheme for making 
compounds 6 and 7 according to an embodiment of the 
present invention; 
FIG. 3 depicts a synthetic scheme for making compounds 
9 and 10 according to an embodiment of the present inven-
tion; 
FIG. 4 presents a synthetic scheme for making compounds 
14 and 15 according to an embodiment of the present inven-
tion; 
FIG. 5 depicts the formulas for the highly active, novel 
compounds of the present invention, compounds 4, 7, 10 and 
15, compared to compounds A, Band C, which were previ-
ously described; and 
FIG. 6 shows results of several agarose gel electrophoresis 
analyses visualized under UV light; these are further dis-
cussed below. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. 
Any publications, patent applications, patents, or other 
references mentioned herein are incorporated by reference in 
their entirety. In case of conflict, the present specification, 
including any definitions, will control. For example, the 
invention disclosed herein is an extension of the experimental 
work that led to application Ser. No. 11/372,671, which was 
published as US 2007/0088081 on Apr. 19, 2007, and which 
is commonly owned with the present application and is incor-
porated herein by reference in its entirety. This previously 
described invention includes parent compounds A, B and C, 
over which the presently disclosed compounds represent an 
unexpectedly surprising and significant improvement. 
In addition, in this application the materials, methods and 
examples given are illustrative innature only and not intended 
to be limiting. Accordingly, this invention may be embodied 
in many different forms and should not be construed as lim-
US 8,497,398 Bl 
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ited to the illustrated embodiments set forth herein. Rather, 
these illustrated embodiments are provided so that this dis-
closure will be thorough and complete, and will fully convey 
the scope of the invention to those skilled in the art. Other 
features and advantages of the invention will be apparent 
from the following detailed description, and from the claims. 
4 
L1210 cells are mouse leukemia cells and are a standard 
well used benchmark for evaluating cytotoxicity of new drug 
systems, especially polyamine containing drugs. 
Chinese hamster ovary cells (CHO cells) have an active 
polyamine transporter. This cell type is very susceptible to 
drugs which use the polyamine transporter system to gain 
access to cells (i.e. polyamine conjugates). 
Chinese hamster ovary cells which are chemically mutated 
to be polyamine transport-deficient will be referred to as the 
CHO-MG cell line. This cell type should have lower suscep-
tibility to polyamine conjugates which use the polyamine 
transporter to gain access to cells, since it does not have an 
active transporter to facilitate their uptake. 
B16 cells are melanoma, skin cancer cells with highly 
active polyamine transporters. These cells should be very 
susceptible to polyamine conjugates which use the polyamine 
transporter to gain access to cells. 
As used herein, the term "pharmaceutically acceptable 
salt" is intended to describe any form (such as a salt of these 
amine systems with an organic carboxylic acid like acetic 
acid or toluene-sulfonic acid or methane sulfonic acid or an 10 
inorganic acid such as HCl, HBr, phosphoric acid, or a related 
group or prodrug) of a compound of the invention, which, 
upon administration to a subject, provides the mature or base 
compound and does not cause undue harmful side-effects in 
the subject. Pharmaceutically acceptable salts include those 15 
derived from pharmaceutically acceptable inorganic or 
organic bases and acids. Suitable salts include those derived 
from alkali metals such as potassium and sodium, alkaline 
earth metals such as calcium and magnesium, among numer-
ous other acids well known in the pharmaceutical art. 
For example, it is a well-known practice in pharmaceutical 
science to use pharmaceutically acceptable acid salts of 
amine derivatives to facilitate their long storage and dosing as 
aqueous solutions. The examples listed in this invention com-
prise polyamine salts derived from a pharmaceutically 25 
acceptable acid (such as HCl or others) with or without the 
use of a pharmaceutically acceptable carrier (such as water or 
other). Such salts can be derived from either inorganic or 
organic acids, including for example hydrochloric, hydrobro-
mic, acetic, citric, fumaric, maleic, benzenesulfonic, and 30 
ascorbic acids. The pharmaceutical compositions obtained by 
the combination of the carrier and the polyamine salt will 
generally be used in an effective dosage necessary to elicit the 
desired biological effect. This includes its use in an antine-
oplastic effective amount or in a lesser amount when used in 35 
combination with other biologically active agents. 
Mel-A cells are normal melanocytes, skin cells which have 
20 moderately active polyamine transporters. These cells should 
be moderately susceptible to polyamine-conjugates, but less 
so than the B-16 cells. 
"Polyamine" relates to a polyamine compound or a 
polyamine conjugate according to an embodiment of the 
present invention, which have a polyamine message which is 
recognized by the polyamine transport system on the surface 40 
of cells and have enhanced uptake into cells with highly active 
polyamine transporters over those which do not, (e.g., CHO 
vs. CHO-MG cells). 
The term "transporter" is used to describe the cellular 
process of binding and/or importing a chemical entity which 45 
is outside the cell. The chemical entity in this case is the 
polyamine or polyamine conjugate, i.e. a polyamine com-
pound or scaffold covalently attached to an agent such as a 
treatment drug or toxic agent. 
The term "conjugate" is used to describe a polyamine 50 
compound according to the present invention which is asso-
ciated with, for example, covalently bound, to a treatment 
agent (e.g., a cytotoxin such as an anthracenyl methyl unit) or 
As noted above, because cancer cells rely on polyamine 
transport in order to sustain their growth rate, this provides an 
opportunity to selectively target rapidly dividing cancer cells 
via their heavy reliance on polyamine import. Drug-
polyamine conjugates, which attach a smart polyamine mes-
sage to a known cytotoxic agent, have been shown to have 
enhanced cytotoxicity to cancer cells (mouse melanoma, 
B-16 cells) over their normal cell counterparts (Mel-A) in 
vitro. Previous anthracene-polyamine conjugates described 
in U.S. Pat. No. 7,001,925 are mono-substituted analogues 
with good selectivity for targeting the PAT. This disclosure 
details the synthesis and superior PAT targeting abilities of a 
di-substituted series of anthracene-polyamine conjugates and 
other arylalkylpolyamines (di-substituted benzyl and naph-
thyl analogues). 
The PAT targeting selectivity was determined using a Chi-
nese hamster cell assay. The CHO wild type cells have active 
polyamine transport activity and therefore should be very 
susceptible to the polyamine conjugate and give low IC50 
values. The IC50 value is the concentration of the drug 
required to kill 50% of the relative cell population. The lower 
the value the more cytotoxic the drug is to that cell type. In 
contrast, the mutant CHO-MG cells, which have no PAT 
activity are not as sensitive to the polyamine conjugate (which 
is unable to enter these cells via the defective PAT) and give 
higher IC50 values. We express these as a ratio of the IC50 
valueinCHOMG/IC50 value in CHO. Thehighertheratiothe 
more PAT selective is the polyamine conjugate drug. Cyto-
toxic compounds, which do not use the PAT for cellular entry, 
would give ratios near 1. 
The previous most selective compounds were the naphthyl to a known agent having anti-cancer properties, e.g., doxoru-
bicin. 55 and anthracene-homospermidine conjugates (with CHO MG/ 
CHO IC50 ratios near 150). These are described in application 
Ser. No. 11/372,671, which was published as US 2007/ 
0088081 on Apr. 19, 2007, and which is commonly owned 
"Cell selectivity" denotes the ability of a polyamine or 
polyamine conjugate of the present invention to preferentially 
enter in enhanced levels cells with highly active polyamine 
transporters (e.g. CHO cells or B16 melanoma cells) over 
those that have lowerpolyamine transport activity (e.g. CHO- 60 
MG cells or Mel-A cells). 
"IC50 value" is the concentration of drug needed to kill 
50% of the relative cell population. The lower the value the 
more cytotoxic the drug is to that cell type. 
"K, value" reflects the affinity of the drug architecture for 65 
the polyamine transporter. The lower the value of the K,, the 
higher the affinity of the drug for the polyamine transporter. 
with the present application and is incorporated herein by 
reference in its entirety, as noted above. Surprisingly, it has 
been discovered that by repeating this message (homosper-
midine) on the other side of the molecule we were able to 
dramatically and unexpectedly improve the PAT targeting 
(e.g. CHOMG/CHO IC50 ratio>2200) ability of these new 
compounds (4, 7, 10 and 15). The novel compounds of the 
present invention are synthesized via the synthetic schemes 
illustrated in FIGS. 1-4. In these synthetic schemes, the 
US 8,497,398 Bl 
5 
reagents used are as follows: a) LiAIH4/THF; b) PCC/ 
CH2Cl2; c) 25% MeOH/CH2Cl2; 2-d) 50% MeOH/CH2Cl2/ 
NaBH4; e) 4N HCl/EtOH. 
Synthetic Preparation of the Novel Compounds 
Compound3 
( 4-tert-Butoxycarbonylamino-butyl)-( 4-{[l 0-( { 4-
[ tert-butoxycarbony 1-( 4-tert-butoxycarbony lamino-
butyl )-amino ]-butylamino }-methyl)-anthracen-9-
ylmethyl]-amino }-butyl)-carbamic acid tert-butyl 
ester 
To a stirred solution of 2 (845 mg, 2.35 mmol) in 25% 
MeOH/CH2Cl2 (20 mL ), was added a solution of Anthracene-
9, 10-dicarbaldehyde (250 mg, 1.07 mmol) in 25% MeOH/ 
CH2Cl2 (15 mL) under N2. The mixture was stirred at room 
temperature overnight until the imine formation was com-
plete (monitored by 1 H NMR (CDC13) signal at 11.40 ppm 
disappeared). The solvent was removed in vacuo, the solid 
residue dissolved in 50% MeOH/CH2Cl2 (40 mL) and the 
solution was cooled to 0° C. NaBH4 (6.42 mmol) was added 
in small portions to the solution and the mixture was stirred at 
6 
complete (monitored by 1 H NMR (CDC13) signal at 11.40 
ppm disappeared). The solvent was removed in vacuo, the 
solid residue dissolved in 50% MeOH/CH2Cl2 (40 mL) and 
the solution was cooled to 0° C. NaBH4 (6.53 mmol) was 
5 added in small portions to the solution and the mixture was 
stirred at rt overnight. The solvent was removed in vacuo, the 
solid residue dissolved in CH2Cl2 (50 mL) and washed with 
10% aq. Na2C03 solution (3x30 mL). The CH2Cl2 layerwas 
separated, dried over anhydrous Na2S04, filtered and 
10 removed in vacuo to give an oily residue. The oil was purified 
by flash colunm chromatography to yield the product 6 as a 
pale yellow viscous oil (60%), Rf=0.3 (7% MeOH/0.5% 
NH40H/CH2Cl2; 
1 H NMR (CDC13) o 8.12 (m, 2H), 7 .50 (m, 
15 
2H), 7.38 (s, 2H), 4.87 (brm, 2H), 4.19 (s, 4H), 3.10 (m, 12H), 
2.73 (t, 4H), 1.65-1.35 (m, 52H); 13C NMR (CDCl3) o 155.9, 
155.4, 135.3, 132.0, 125.7, 125.4, 124.2, 79.1, 51.7, 49.7, 
46.9, 46.7, 40.2, 28.5, 28.5, 27.4, 26.7, 26.1, 25.8. HRMS 
(FAB) rn/z calcd. for C48H82N608 (M+Ht 871.6267, found 
20 871.6211. 
Compound 7 
rt overnight. The solvent was removed in vacuo, the solid 
residue dissolved in CH2Cl2 (50 mL) and washed with 10% 25 
aq. Na2C03 solution (3x30 mL). The CH2Cl2 layerwas sepa-
rated, dried over anhydrous Na2S04, filtered and removed in 
vacuo to give an oily residue. The oil was purified by flash 
colunm chromatography to yield the product 3 as a pale 
yellow viscous oil (92%), Rf=0.3 (5% MeOH/0.5% NH40H/ 30 
CH2Cl2; 
1H NMR (CDC13) o 8.36 (d, 4H), 7.50 (d, 4H), 7.48 
(m, 2H), 4.82 (br m, 2H), 4.68 (s, 4H), 3.13 (m, 12H), 2.87 (t, 
4H), 1.65-1.30 (m, 52H); 13C NMR (CDCl3) o 155.9, 155.4, 
131.9, 129.9, 125.6, 124.8, 79.1, 78.9, 53.5, 50.3, 46.9, 46.7, 
46.0, 40.2, 28.6, 28.5, 27.5. HRMS (FAB) rn/z calcd. for 35 
C52H84N608 (M+Hr 921.6423, found 921.6414. 
N-( 4-Amino-butyl)-N'-( 4-{[ 4-( 4-amino-butylamino )-
butylamino ]-methyl }-naphthalen-1-ylmethyl)-bu-
tane-1,4-diamine, Hydrochloride salt 
A solution of BOC-protected 3 (500 mg, 0.57 mmole) was 
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for 
10 minutes. A 4N HCl solution (22 mL) was added to the 
reaction mixture dropwise and stirred at 0° C. for 20 minutes 
and then at room temperature overnight. The solution was 
concentrated in vacuo to give 7 as a yellow solid in 94% yield. 
1H NMR (D20) o 8.20 (m, 2H), 7.78 (m, 2H), 7.72 (s, 2H), 
4.83 (s, 4H), 3.28 (t, 4H), 3.11 (t, SH), 3.04 (t, 4H), 1.85-1.73 
(m, 16H); 13C NMR (D20): 0 131.3, 129.3, 128.6, 128.0, 
123.8, 48.2, 47.3, 47.2, 47.1, 39.0, 24.2, 23.2, 23.1. HRMS 
(FAB) calcd for C28Ho5N6.6HC1 (M+H-6HClt 471.4170. 
Found 471.4155. 
Compound4 
N-( 4-Amino-butyl)-N'-(10-{[ 4-( 4-amino-buty-
lamino )-butylamino ]-methyl }-anthracen-9-ylm-
ethyl)-butane-1,4-diamine, Hydrochloride salt 
40 
Compound9 
A solution of BOC-protected 3 (890 mg, 0.97 mmole) was 
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for 45 
10 minutes. A 4N HCl solution (22 mL) was added to the 
reaction mixture dropwise and stirred at 0° C. for 20 minutes 
and then at room temperature overnight. The solution was 
concentrated in vacuo to give 4 as a yellow solid in 95% yield. 
1HNMR(D20) o 8.19 (d, 4H), 7.79 (d, 4H), 4.83 (s, 4H), 3.30 50 
(t, 4H), 3.11 (m, 12H), 1.79 (m, 16H); 13C NMR (D20): o 
129.7, 127.7, 124.7, 124.0, 47.7, 47.2, 47.1, 42.8, 39.0, 24.2, 
23.2, 23.1. HRMS (FAB) calcdforC32H52N6.6HCl [(M+2H-
6HC1)/2t 261.2199. Found261.2199. 
( 4-tert-Butoxycarbonylamino-butyl)-{ 4-[ 4-( { 4-[tert-
butoxycarbony 1-( 4-tert-butoxy carbony lamino-bu-
tyl )-amino ]-butylamino }-methyl)-benzylamino ]-
butyl}-carbamic acid tert-butyl ester 
To a stirred solution of 2 (885 mg, 2.46 mmol) in 25% 
MeOH/CH2Cl2 (20 mL), was added a solution ofBenzene-
1,4-dicarbaldehyde (150 mg, 1.12 mmol) in 25% MeOH/ 
CH2Cl2 (15 mL) under N2. The mixture was stirred at room 
temperature overnight until the imine formation was com-
plete (monitored by 1H NMR (CDC13)). The solvent was 
removed in vacuo, the solid residue dissolved in 50% MeOH/ 
Compound6 
( 4-tert-Butoxycarbonylamino-butyl)-( 4-{[ 4-( { 4-[tert-
butoxycarbony 1-( 4-tert-butox y lcarbony lamino-bu-
tyl )-amino ]-butylamino }-methyl)-naphthalen-1-ylm-
ethyl]-amino }-butyl)-carbamic acid tert-butyl ester 
To a stirred solution of 2 (468 mg, 1.30 mmol) in 25% 
MeOH/CH2Cl2 (20 mL), was added a solution ofNaphtha-
lene-1,4-dicarbaldehyde (200 mg, 1.09 mmol) in 25% 
MeO H/CH2Cl2 ( 15 mL) under N2. The mixture was stirred at 
room temperature overnight until the imine formation was 
55 CH2Cl2 (40mL) and the solution was cooled to 0° C. NaBH4 
(6.71 mmol) was added in small portions to the solution and 
the mixture was stirred at rt overnight. The solvent was 
removed in vacuo, the solid residue dissolved in CH2Cl2 (50 
mL) and washed with 10% aq. Na2C03 solution (3x30 mL). 
60 The CH2Cl2 layer was separated, dried over anhydrous 
Na2SO 4, filtered and removed in vacuo to give an oily residue. 
The oil was purified by flash colunm chromatography to yield 
the product 9 as a pale yellow viscous oil (54%), Rf=0.38 (6% 
MeOH/0.5% NH40H/CH2Cl2; 
1 H NMR (CDC13) o 7 .17 (m, 
65 4H), 4.83 (br m, 2H), 3.68 (s, 4H), 3.06 (m, 12H), 2.55 (m, 
4H), 1.60-1.21 (m, 52H); 13C NMR (CDCl3) o 155.9, 155.4, 
138.8, 128.1, 126.8, 79.1, 78.8, 64.3, 53.5, 49.0, 46.9, 46.7, 
US 8,497,398 Bl 
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40.2, 28.5, 28.5, 27.5, 27.3, 26.6, 26.0, 25.6. HRMS (FAB) 
mlz calcd. for C44H80N608 (M+Ht 821.6110, found 
821.6083. 
Compound 10 
N-( 4-Amino-butyl)-N'-( 4-{[ 4-( 4-amino-butylamino )-
butylamino ]-methyl }-benzyl)-butane-1,4-diamine, 
Hydrochloride salt 
A solution of BOC-protected 9 ( 495 mg, 0.60 mmole) was 
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for 
10 minutes. A 4N HCl solution (22 mL) was added to the 
reaction mixture dropwise and stirred at 0° C. for 20 minutes 
and then at room temperature overnight. The solution was 
concentrated in vacuo to give 4 as a yellow solid in 93% yield. 
1HNMR(D20) 07.59 (m, 4H), 4.30 (s, 4H), 3.17 (t, 4H), 3.11 
(t, SH), 3.05 (t, 4H), 1.78 (m, 16H); 13C NMR (D20): 0 132.4, 
130.9, 64.3, 51.1, 47.4, 47.3, 47.1, 39.3, 24.5, 23.4, 23.3. 
HRMS (FAB) calcd for C24H48N6.6HC1 [(M+2H-6HC1)/2]+ 




protected homospermidine 2 (1.44 g, 4.011 mmol) in 25% 
MeOH/CH2Cl2 (10 mL) was added via an addition funnel. 
The reaction mixture was stirred overnight under a N2 atmo-
5 sphere. Loss of the starting material was monitored via 1 H 
NMR spectroscopy and the disappearance of the aldehyde 
proton at 10.21 ppm. Upon conversion of the starting mate-
rial, the solvent was extracted in vacuo and the crude material 
10 was redissolved in a solution of50% MeOH/CH2Cl2. To this 
new solution was added NaBH4 (0.45 g, 11.9 mmol) at 0° C. 
The solution was stirred overnight under a N2 atmosphere. 
The solvent was removed in vacuo and flash colunm chroma-
15 tography (1 % NH40 HI 5% CH3 0 H/CH2 Cl2) provided a mix-
ture of the co-eluting Boe-protected homospermidine 2 and 
the desired product 14 (1.08 g). To aid in the chromatographic 
separation of 14 and 2, another reaction was carried out. The 
20 mixture was dissolved in THF ( 45 mL) and stirred for 20 min 
at 0° C. A solution of2-(tert-butoxycarbonyloyimino )-2-phe-
nylacetonitrile) (BOC-ON, 0.23 g, 0.93 mmol) was added 
dropwise with constant stirring. After the addition was com-
25 plete, the reaction was stirred for 2 h at 0° C. under a N2 
atmosphere. Upon completion, the solution was concentrated 
in vacuo, the residue was redissolved in CH2Cl2, and washed 
with a saturated aqueous Na2C03. The organic layer was 
Trimethyl-1,3,5-benzenetricarboxylate 11 (2 g, 7 .9 mmol, 
Acros Chemicals) in dry THF (30 mL) was added through a 
pressure-equalized addition funnel into a 250-mL flask con-
taining LiAIH4 (0.90 g, 23.6 mmol) in dry THF (65 mL) at 0° 30 
C. under a N2 atmosphere. The mixture was allowed to warm 
separated, dried over anhydrous Na2S04 filtered and concen-
trated. Flash colunm chromatography of the residue gave 
pure 14 as colorless oil (79 mg). Yield: 6%. Rf=0.35 (1 % 
NH40H/6.5% CH30H/CH2Cl2); 
1H NMR (300 MHz, 
CDC13) o 7.14 (s, 3H, aromatic), 4.69 (s, 3H, NH), 3.75 (s, 
to room temperature and was then stirred for 4 h. The reaction 
was quenched by the slow addition of a 1: 1 mixture of Celite 
and KHS04. The suspension was filtered, and the Celite was 
washed with MeOH (100 mL). The solvent was removed 35 
under reduced pressure and triol 12 was obtained in 78% yield 
(1.05 g). 1 H NMR of the product matched that of the authentic 
material: 1HNMR (300MHz, DMSO) o 7.18 (s, 3H), 4.50 (s, 
6H, CH2), 3.15 (m, 18H, CH2), 2.65 (t, 6H, CH2), 1.65-1.15 
(m, 78H, CH2, CH3); 13C NMR (CDCl3): 0 156.0, 155.6, 
140.5, 126.7, 79.3, 79.2, 54.1, 49.5, 47.1, 46.9, 40.4, 28.7, 
6H). 
Compound 13 
40 28.6, 27.6, 27.5, 26.8, 26.1, 25.8. HRMS (FAB)m/z calcdfor 
C63Hl 17012N9 (M+Hr 1192.8894, found 1192.9008. 
1,3,5-Triformyl benzene 
1,3,5-Tris(hydroxymethyl)benzene: (1.05 g, 6.25 mmol) 45 
was suspended in CH2Cl2 (25 mL), and solid pyridinium 
chlorochromate (5.98 g, 27.74 mmol) was added. After 30 
min of stirring, the reaction mixture was diluted with acetone 
(10 mL), and was allowed to stir for 3 h. The precipitated 
chromium salts were filtered off and washed with CH2Cl2. 
50 
The organic phase was washed with a saturated solution of 
aqueous Na2C03 three times, and dried over anhydrous 
Na2S04. Filtration through a silica gel colunm eluting with 
CH2Cl2 afforded 13 as white crystals (51 %, 0.51g).
1H NMR 55 




N-( 4-Amino-butyl)-N-(3,5-bis-{ [ 4-( 4-amino-buty-
lamino )-butylamino ]-methyl }-benzyl)-butane-1,4-
diamine, nona-Hydrochloride Salt 
Compound 14 (79 mg, 0.066 mmol) was dissolved in abso-
lute ethanol (8 mL) and stirred at 0° C. for 10 minutes. 4N HCl 
solution (10 mL) was added dropwise to the reaction mixture 
and stirred at 0° C. for 20 minutes and then at room tempera-
{ 4-[3,5-Bis-( { 4-[tert-butoxycarbonyl-( 4-tert-butoxy-
carbonylamino-butyl)-amino ]-butylamino }-methyl)-
benzylamino ]-butyl}-( 4-tert-butoxycarbonylamino-
butyl)-carbamic acid tert-butyl ester 
60 ture overnight. The solution was concentrated in vacuo to give 
15 as a white solid in 97% yield (59 mg). 1 H NMR (300 MHz, 
D20) o 7.64 (s, 3H, aromatic), 4.32 (s, 6H, CH2), 3.18 (t, 6H, 
CH2), 3.07 (m, 18H, CH2), 1.77 (m, 24H, CH2); 
13C NMR 
1,3,5-Triformyl benzene (0.180 g, 1.11 mmol) was dis-
solved in 25% MeOH/CH2Cl2 (10 mL). A solution of Boe-
65 (D20): o 135.6, 135.1, 53.2, 49.8, 49.7, 41.7, 26.9, 25.8, 25.7; 
HRMS (FAB) m/z calcd for C33H78N9Cl9 (M+H-9HC1)+ 
592.5749, found 592.5749. 
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TABLE 1 
Elemental analyses for compounds 
c H N 
Cmpd No. Molecular Formula Cal ed. Found Calcd. Found Calcd. Found 
C52H84N60 80.4H20 67.27 67.23 9.21 9.07 9.05 8.87 
4 C32H58N6Cl61.3H20 50.38 50.36 8.01 8.05 11.02 10.84 
C4sHs2N60s 66.18 65.99 9.49 9.47 9.65 9.57 
7 C28H56N6Cl62.5H20 45.79 45.94 8.37 8.25 11.44 11.37 
9 C44H80N60 80.2H20 64.07 64.03 9.83 9.84 10.19 9.94 
10 C24H54N6Cl6 45.08 44.85 8.51 8.43 13.14 12.86 
14 C63Hu 7012N90.5H20 62.97 9.90 10.49 62.85 
15 C33H78N9Cl9 1.5H20 41.85 8.62 13.31 41.90 
TABLE2 
CHO studies 
CHO MG CHO CHOMG/CHO 
Cmpd ICso (µM) IC50 (µM) IC50 Ratio 
A 66.7 (±4.1) 0.45 ± 0.10 148 
B >100 0.6 ± 0.2 >164 
c >1000 >1000 NA 
4 >100 0.045 ± 0.003 >2222 
7 >100 0.12 ± 0.03 >833 
10 50.2 ± 3.8 0.074 ± 0.010 677 
15 >500 >500 NA 
TABLE3 
L1210 studies 
L1210 L1210 +DFMO 
K;(µM) IC50 (µM) IC so (µM) 
A 1.8 ± 0.1 0.30 ± 0.04 0.09 ± 0.01 
B 3.8 ± 0.5 0.50 ± 0.03 0.43 ± 0.02 
c 4.5 ± 0.8 36.3 ± 8.4 ND 
4 0.39 ± 0.05 0.78 ± 0.07 0.22 ± 0.08 
7 0.17 ± 0.02 0.25 ± 0.08 ND 
10 0.52 ± 0.11 0.16 ±0.01 0.36 ± 0.03 
15 0.49 ± 0.02 122.3 ± 8.1 49.3 ± 10.0 
Biological Evaluation of the Compounds 
The biological evaluation of these compounds is shown in 
Table 2. As indicated therein, compound 4 was found superior 
in terms of targeting CHO cells with active polyamine trans-
port showing a surprising IC50 ratio of>2200! This is an order 
of magnitude higher than found with our previously reported 
compounds A and B. In our earlier report, compound C was 
shown to be somewhat unstable to cellular oxidases and par-
tially degraded into homospermidine. As such, we were 
unable to measure its cytotoxicity and C had an IC50 






spermidine, we were able to rank the binding affinity of the 
compounds for the PAT. Low K, values mean the compound 
has a high binding affinity for the PAT. As shown in Table 3, 
20 
the di-substituted analogues 4, 7, and 10 all had significantly 




Compound 4 as a Topoisomerase II (Topo-II) Catalytic 
Inhibitor: 
Topoisomerase Ilalpha (Topo Ila) is known to be highly 
expressed in rapidly multiplying cells such as cancers. In 
sheath tumors of the peripheral nerves, a difficult to treat 
cancer, high expressed levels ofTopo Ila are associated with 
poor prognosis and survival. 
Previously, we have tested several branched polyamine-
anthracene and acridine conjugates for their ability to inhibit 
Topo Ila and the results were shown to be positive for all 
tested conjugates (see Phanstiel et al., J. Org. Chem., 2000, 
65, 5590-5599; which is incorporated herein by reference in 
35 its entirety). Thus the linear polyamine-anthracene conju-
gates herein disclosed (e.g., compound 4) were evaluated as 
Topo II inhibitors.A well established in vitro Topo II assay (as 
used previously) allowed us to determine whether these new 
40 
conjugates (previously described compound A and novel 
compound 4 of the present invention) have the ability to 
inhibit Topo II by preventing Topo Ila from decatenating (i.e., 
disentangling) kinetoplast DNA (kDNA). It was concluded 
that conjugates A and 4 were catalytic Topo-II inhibitors, 
45 where inhibition correlated positively with an increase in 
drug concentration. Compound 4 was superior to the previ-
ously described parent compound A, where good inhibition 
was observed at a concentration of 5 µM with compound 4 
(i.e., significant kDNA remained undecatenated in the top 
50 well of FIG. 6, indicating Topo II inhibition). In contrast, 
significantly less inhibition was observed atthe same concen-
tration (5 µM) with compound A. Both conjugates were com-
pared to a known inhibitor, Berenil (labeled' B' in the last lane 
Cytotoxicity experiments were also performed in murine 
leukemia cells (L1210, Table 3) with and without the pres- 55 
ence of difluoromethylornithine (DFMO), a known inhibitor 
of each gel in FIG. 6), as a control. 
In this regard, FIG. 6 shows inhibitionoftopoisomerase II. 
A negative image of agarose gel electrophoresis is visualized 
under UV light. Drugs were incubated with kDNA (200 ng) 
and Topo Ila ( 4 units) in reaction buffer prior to loading onto 
the gel. Neg. Control (-): kDNA only; Pos. Control ( + ): 
of omithine decarboxylase (the enzyme responsible for 
polyamine biosynthesis ). Typically, when one blocks the abil-
ity of cells to synthesize polyamines, the cells respond by 
increasing their import of extracellular polyamines via PAT. 
Therefore, if our drugs are PAT-selective we should see a 
lowering of their respective IC50 values in the presence of 
DFMO, a molecule which facilitates the drug's import. 
Indeed, as shown in Table 3, the IC50's are lower in the 
presence ofDFMO, except for 10. 
K, values indicate the binding affinity of the compounds for 
the PAT. Using competition experiments with radiolabeled 
60 kDNA+ Topo II (without conjugate); Inhibitory Control (B, 
rightmost lane): Berenil (50 µM). All other lanes contain the 
corresponding conjugate at the listed µM concentrations. 
Positive Topo II activity is shown by the formation of nicked 
open circular (NOC) DNA (middle band) and covalently 
65 closed circular (CCC) DNA (bottom band). Inhibition is 
shown by the negative activity ofTopo II where kDNA (top 
band) is not decatenated and remains in the well. 
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When kDNA was not incubated with drug and Topo II 
(negative control), no migration occurred on the gel and the 
kDNA remained in the well as expected, which was indicated 
by the single top band visualized in the well. When kDNA 
was incubated with Topo II in the absence of drug, the top 
band in the well disappeared completely while two bands 
representing the two decatenated products could be seen. This 
showed that the enzyme had good activity and only inhibition 
rather than enzyme inactivity produced the band in the top 
well upon added drug. Berenil, a known inhibitor at 50 µM 
showed good inhibition as expected and gave most of the 
kDNA remaining in the well. 
12 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
5 tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
That which is claimed: 
1. An aromatic hydrocarbon di-substituted with a 
10 polyamine, said di-substituted aromatic hydrocarbon having 
the formula of compound 4: 
Accordingly, compound 4 appears to be a novel inhibitor of 
Topo II and, as such, is a potential agent for use against 15 
cancers where increased levels of the enzyme play a signifi-
cant role in the pathogenesis of the disease. 
4 
In addition, novel compounds 4, 7, 10 and 15 represent the 
next generation of smart drugs and a major advance in terms 
of PAT-selective agents. These compounds have similar cyto-
toxicities to the original series A-C in L1210 cells, but are 
significantly more efficient in entering cells with active 
polyamine transporters (e.g. CHO cells). This is represented 
H 
20 H2N~N~N 
by their 10-fold increase in potency in the CHO wild type cell 
line over their A-C counterparts. Additionally, compounds 4 25 
andA may also be used as Topo II catalytic inhibitors in vitro 
as they showed good inhibition in a well-established assay. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-








or a pharmaceutically acceptable salt thereof. 
2. Compound 4, wherein compound 4 is synthesized 











reacting compound 1 with compound 2 to provide compound 15 
3, and removing the protecting groups of compound 3 to 
provide compound 4, wherein a is LiAIH4/THF; b is PCC/ 
CH2 Cl2 ; and c is 25% MeOH/CH2 Cl2 . 
3. A pharmaceutical composition comprising: 
a compound comprising the formula of compound 4: 
or a pharmaceutically acceptable salt thereof; and 
a pharmaceutically acceptable carrier. 
* * * * * 
14 
H 
N~N~NH2·6HCl 
H 
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